CFTR and autosomal dominant polycystic kidney disease: Cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors, including CFTRinh-172, have been developed as therapeutic candidates to treat secretory diarrhea and autosomal dominant polycystic kidney disease.